Interview: Jim Keon, President of Canadian Generic Pharmaceutical Association (CGPA)
08.10.2013
Related Interviews
Michael Gorenstein, CEO, The Cronos Group, Canada
“If you are trying to be everything to everybody, you end up being nothing to no one”—Michael Gorenstein, CEO of The Cronos Group talks to PharmaBoardroom about his unusual career…
Bob McLay – Vice President and General Manager, Sobi Canada
Bob McLay, vice president and general manager of Sobi in Canada, discusses how innovation and collaboration with regulators and payers are helping Sobi to bring its medicines to Canadians suffering…
Neil Closner – CEO, MedReleaf, Canada
With already 20 percent of market share in the medical cannabis sector in Canada, MedReleaf is getting ready for the upcoming legalization of cannabis for recreational use. The company’s CEO…
Biosimilars / Sandoz CEO Richard Saynor on Five Crucial Market Trends
In conversation at the FT’s Global Pharmaceutical & Biotechnology Conference last month, Sandoz CEO Richard Saynor outlined the current status of the biosimilars industry, the differences between the European and…
Turkey / Biosimilars on the Rise
With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars. The share of biotechnological…
US Generics & Biosimilars / Five Takeaways from Access! 2021
Dan Leonard of the Association for Accessible Medicines (AAM) highlights five key takeaways from the organisation’s remote but dynamic annual conference, and how the US generics and biosimilars industry might…
Latest Report
